Select Page ::

‘Dr. Stone’ season 2 spoilers: TMS drops new teaser and here’s what it revealed about Senku and the ‘Stone Wars’ arc – EconoTimes

Posted on July 21, 2020 by Danzig

As the release of the much-awaited Science-themed anime gets nearer, its followers are getting excited since there are a lot of things to anticipate. It was already revealed that Dr. Stone season 2 is set to feature the Stone Wars arc, and now more details about it have been disclosed.

In any case, this Japanese animation was renewed not long after the finale of the first season aired. It is clear that Dr. Stone is a big hit; thus TMS did not think twice about ordering for a second season to be made immediately.

Spoilers - What to expect

When the renewal was announced, it also provided a bit of teaser as to what can be expected in the upcoming new season of Dr. Stone. Aside from sharing about the new arc, there were also scenes that showed the lead Senku and his friends, General and Chrome, doing a fist bump.

The three also made a pact to stay and keep fighting together, perhaps, until they win over all their enemies. Now, in the latest trailer that was unveiled by TMS Entertainment earlier this month, more spoilers for Dr. Stone season 2 were shared.

In the first teaser, it was not shown who Senku and his group are set to fight, but in this new video, it was confirmed that the opponent is still Tsukasa and his empire. With the non-believers in Science as their rival, the battle has been called the Kingdom of Science! All forces advance!

It means that this will be a war that will be Science against the use of force from Tsukasas empire. Surely, Tsukasa and his army will fight using bare hands and traditional tools while Senkus team who has been preparing for this battle since season 1 will be attacking with their advanced gadgets, weapons, and simple strategies based on Science.

The first season was released with a total of 24 episodes and the same is expected for the second installment. Also, it was teased that Senku will also build a new civilization while also trying to solve the mystery of petrification. On the other hand, Tsukasa will also form a new kingdom in Stone Wars.

Release date

The exact release date for the next installment of Dr. Stone was not stated. However, based on TMS new poster, this anime is coming in January 2021. Check out the trailer below:

See more here:

'Dr. Stone' season 2 spoilers: TMS drops new teaser and here's what it revealed about Senku and the 'Stone Wars' arc - EconoTimes

Trending News Corona impact on Reishi Mushroom Extract Market Report Forecast to 2025 by Global Market Insights, Key Companies and Driving Trends|…

Posted on July 21, 2020 by Danzig

The global Reishi Mushroom Extract Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Reishi Mushroom Extract Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Reishi Mushroom Extract Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Reishi Mushroom Extract Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Reishi Mushroom Extract Market.

Leading players of the global Reishi Mushroom Extract Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Reishi Mushroom Extract Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Reishi Mushroom Extract Market. It also provides useful recommendations for new as well as established players of the global Reishi Mushroom Extract Market.

Final Reishi Mushroom Extract Report will add the analysis of the impact of COVID-19 on this Market.

Reishi Mushroom Extract Market competition by top manufacturers/Key player Profiled:Vitacost,Swanson,Life Extension,Natures Answer,Natures Way,New Chapter,Solaray,Solgar,Source Naturals,Vital Nutrients,Bio-Botanica

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Reishi Mushroom Extract Market:

The global Reishi Mushroom Extract market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.

Segmentation by Product:

PowderLiquid

Segmentation by Application:

Health Care ProductsEssential OilOthers

Competitive Analysis:

Global Reishi Mushroom Extract Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Reishi Mushroom Extract Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Reishi Mushroom Extract Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The report offers in-depth assessment of the growth and other aspects of the Reishi Mushroom Extract market in important countries (regions), including:

North America(United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2381928

Table of Contents

Report Overview:It includes major players of the global Reishi Mushroom Extract Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Reishi Mushroom Extract Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Reishi Mushroom Extract Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Reishi Mushroom Extract Market by application, it gives a study on the consumption in the global Reishi Mushroom Extract Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Reishi Mushroom Extract Market are profiled in this section. The analysts have provided information about their recent developments in the global Reishi Mushroom Extract Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Reishi Mushroom Extract Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Reishi Mushroom Extract Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Reishi Mushroom Extract Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

See more here:

NEWS UPDATE: A Reduction in Government Support Blows New Challenges at the Wind Energy Industry, Sees Kline – GlobeNewswire

Posted on July 21, 2020 by Danzig

PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) --

UPDATE FOR OUR JULY 20, 2020 RELEASE

Please note that the following sentence has been updated. For reference, the original sentence follows.

Update

In emerging markets, Suzlonthe largest OEM in terms of cumulative capacity installed in Indiawas in financial distress but has recently concluded debt restructuring in alignment with all lenders.

Original

In emerging markets, Suzlonthe largest OEM in terms of cumulative capacity installed in Indiais now on the brink of bankruptcy.

View full release at this link or below.

A Reduction in Government Support Blows New Challenges at the Wind Energy Industry, Sees Kline

PARSIPPANY, NJ, July 20, 2020 Driven by support from various governments, wind energy has grown rapidly since 2000. As a result, global lubricant demand in the wind energy industry has increased in line with the growth in total installed wind energy capacity. From 2008 to 2019, the global wind energy installed capacity grew at a CAGR of 16.6%, and lubricant consumption grew by a CAGR of 13%, shows Klines recently published Lubricants for Wind Turbines: Global Market Analysis and Opportunities study.

As the industry matures, governments are phasing out monetary incentives and emphasizing supporting legislation such as renewable energy targets, grid priority, and land allocations. In the aftermath of the COVID-19 pandemic, government policies to jumpstart economies will put more pressure on finances; this may accelerate the phasing out of monetary incentives. The industry will have to learn to stand on its own.

To learn more about this changing market, ACCESS our recently held webinar,Outlook for Wind Turbine Lubricant Demand in the Current Economic Environment.

Currently, OEMs are experiencing tough market conditions due to the phase-out of subsidies. Senvion, a German wind turbine manufacturer, filed for bankruptcy in April 2019. Nordex recently announced a merger with the Spanish renewable energy company, Acciona Windpower. In emerging markets, Suzlonthe largest OEM in terms of cumulative capacity installed in Indiawas in financial distress but has recently concluded debt restructuring in alignment with all lenders. The capital expenditure of wind power projects has also dropped by 10% to 15% after the transition from feed-in tariffs to reverse auctions.

The wind energy sector is dominated by a few global players, and OEM ties are increasingly important. The supply base for lubricants used in wind turbines is also largely consolidated in the hands of a few key companies. Global majors such as Castrol, ExxonMobil, and Shell are present in almost all markets. The study shows that Castrol is the global leader in the lubricants market for wind energy with a supply footprint covering all major regions.

To succeed in this business, suppliers need to have a proven track record of products meeting OEMs performance requirements, the ability to demonstrate cost savings, and OEM tie-ups, comments Milind Phadke, Vice President, Energy at Kline. Castrol leads the market due to a strong product portfolio and tie-ups with such OEMs as Vestas and Siemens Gamesa, giving the company access to their first-fill and warranty fill business. This gives Castrol a strong position in Europe, North America, and India, along with a global leadership position.

Srikanth Visvanathan, Global Marketing Director for Castrol Commercial Vehicles and Industrial, says: Our leading position in wind, with 33% of the market, reflects our commitment to providing innovative lubricants and service solutions. With BP and our affiliate Onyx Insight, we can provide improved efficiency, lower downtime, and lower the levelized cost of energy for our customers.

We are the trusted supplier for thousands of wind turbine OEMs and wind farm operators worldwide, from first-fill through the entire working life, providing them with the ultimate lubricants and optimized service solutions that help extend the asset life. Castrols combination of industry experts and suite of wind solutions is designed to drive the success of the wind sector, delivering high-grade lubricants, advanced analytics, and expert training to upskill wind technicians.

Observing the rapid growth in the industry, new participants are trying to enter this market. These include mid-tier lubricant companies with a presence in the synthetics business. However, new suppliers face several entry barriers, including a rigorous approval process, a good track record as a supplier, and a performance history of new product development. The industry is risk-averse, and this results in an extension of warranties and the use of the same products outside the warranty period.

Despite the reduction in government support, the wind energy sector continues to receive support. Germany is likely to support local OEMsSiemens Gamesa, Enercon, and Nordexwhich have a strong global footprint. Governments are unlikely to withdraw complete support for the wind energy industry, as this will be difficult politically. However, they may reduce their support by decreasing the quantum of subsidies that they currently provide. Monetary subsidies will be replaced with favorable legislation (as in Germany), such as renewable energy targets, grid priority, and land allocations.

As per the GWEC outlook for spring 2020, new installations should grow at a CAGR of 4.1%, from 60.4 GW in 2019 to 73.4 GW in 2024. As a result, total installed wind energy capacity is estimated to grow at a CAGR of 9.1% over the forecast period to reach 1,005.0 GW by 2024 from 650.1 GW in 2019. While not as strong as in previous years, the growth in new installations will continue to drive growth in the lubricants market. Besides the growth, other factors, including green image and high-margin business for lubricant marketers, will attract lubricant suppliers.

The information is sourced from our just-published studyLubricants for Wind Turbines: Global Market Analysis and Opportunities.

About Kline Kline is a worldwide consulting and research firm dedicated to providing the kind of insight and knowledge that helps companies find a clear path to success. The firm has served the management consulting and market research needs of organizations in the agrochemicals, beauty & personal care, chemicals & materials, energy, and life sciences industries for more than 60 years. For more information, visit http://www.KlineGroup.com.

14 Ingenious Gadgets That Will Improve Your Life 2020 | The Strategist – New York Magazine

Posted on July 21, 2020 by Danzig

When truly wireless earbuds were first released, it felt like a breakthrough technological moment. This wasnt quite the moon landing, but it was an innovation that streamlined a cluttered part of our everyday lives. In honor of Ingenious Design Week, we tracked down products, both from our archives and beyond, that can simplify or improve our lives. There were plenty to choose from. Earbuddyz Earpod covers will keep your AirPods in your ears no matter how far you run or how much you sweat. The donut-shaped Famatel roller is an extension cord (and extension cord holder) that isnt an eyesore. And the Anker Nebula Capsule projector has everything you need to turn your backyard into a movie theater, contained in a device the size of a soda can. What connects them all is their ingenuity. Features big and small that may not save the world but just might save the day. Here are our favorites.

For most of my life, I have held a decidedly who cares attitude toward extension cords, says Strategist writer Liza Corsillo. I appreciated their utility, but my feelings stopped there.Then she discovered the Famatel. It comes rolled up inside a compact, bagel-shaped, silicon spindle. The lime-green halves of the bagel are flexible and can be turned inside out for quick winding and flipped back down to keep any unused cord neat and tidy. Plus, unlike other extension cords, it doesnt have that garage-only aesthetic: My Famatel Roller is almost a decorative item, Corsillo says.

This powerstation has 11 outlets two AC ports, four USB ports, two type-C ports, two DC 12V ports, and a vehicle 12V output all of which can be used at the same time. Strategist contributor Steven John says it rendered all of his old camping battery packs obsolete.I typically lug all manner of chargers a bunch of little guys for phones, a slightly bigger one for larger devices, plus a generator in case of a storm. But the River takes the place of all those, he says. Once its charged up, the device can hold that charge for a year.

Most charging cables stick straight out from your phone while in use. So if youre checking Twitter in bed, the cable is bent against your stomach. If youre charging your phone while driving, the cable is probably bent back on itself in the cupholder. Its not comfortable for you, and its not good for the cable, which will eventually fray and break. But thats not the case with Aukeys right-angle cables, John says. Since the bend is built into the connector, theres no stress on the cable. Even if there were, the cables have been rated to last more than 10,000 bends, he says.

With this outlet, whether youre using a space heater or a flat iron, youll never forget to turn it off. You push a button to turn the power on, use your device as you ordinarily would, then walk away when youre done, says Strategist contributor Alison Freer. Its like an egg timer for your electronic devices and comes in a power-strip version, too.

If youre outside on a hot day, a personal fan can be the difference between being comfortable or stewing in your own sweat. For Strategist contributor Maggie Coughlan, this miniature fan saved her from the sweltering subway platforms of NYC. At $5, this little gadget is the least amount of money Ive spent for the most comfort, she says. It has a very simplistic design. Theres no on or off switch, you simply pop the fan into your phones lightning port. It weighs in at barely an ounce and is made of soft plastic, so if you catch your fingers in its blades, youll survive unscathed. It will affect your battery, but no more than frantically reloading your Instagram feed.

Strategist columnist Chris Black says his first days of using AirPods were strange and unsettling: The left AirPod did not feel secure, I was afraid that with one wrong nod I was going to lose it, and I would have to return, defeated, to the corded masses. After his left airpod flew out of his ear and tumbled into oncoming traffic one day, he turned to Earbuddy AirPod Covers. They are basically grippy condoms for my AirPods, made from high-performance elastomers, he says. The real magic lies in the extra little piece of plastic that conforms to the groove of your inner ear. I strapped them on and took them for the ultimate test: a sweat-drenched run. They didnt budge. I didnt even have to adjust them once! It was a miracle.

For $15 apiece, you can sync your outlets with your Wi-Fi and thus control them with your phone, says Strategist contributor Lindsey Weber. All of my lamps can now be turned on and off with a swipe I even set timers so that they turn on automatically, both to avoid arriving home to a dark house and to give the appearance that someones home even when no one is. You can get your AC blasting before you get home or turn your slow cooker on from the couch, before you head to the kitchen. Anything you can imagine plugging in and turning on can be controlled with an app.

Watching shows in bed can be a great experience unless youre the kind of person who gets uncomfortable sitting in the same position for too long and at some point you end up in a bizarre yoga position, holding the iPad over your head until your hands start to shake. Strategist contributor Jinnie Lee solved that problem with this oddly designed iPad stand. It can comfortably hold up to a ten-inch device, and its malleable but firm arm can extend 30 inches, making it effortless to stretch, bend, and tilt based on your preferred lying-down position, she says. For me, the stand is perfectly sturdy attached to my headboard, though other mounting options could include nightstands or overhead shelves.

This water-resistant portable speaker has an eight-hour battery life and uses a magnet to attach to the back of your phone, your fridge, or any other metal surface. (It also has a mount for nonmagnetic surfaces.) The Mo expands to create its own sound chamber, which enhances the bass and gives you a fuller listening experience. When youre done with it, just collapse it back down. Its only an inch thick perfect for throwing in your bag or even putting in your pocket.

The size of a can of soda, the Anker Nebula Capsule projector can display your favorite movies, TV shows, and YouTube videos at up to 100 inches. It even has a built-in 360-degree speaker. Pair it with a bare wall or sheet and a good chair and youre ready for a cozy movie night.

This tech-enhanced fire pit will make even the most inept fire builder look like Prometheus himself, says Strategist contributor James Lynch. Once you light the kindling, just tap a button in the app, and airflow in the burn chamber increases automatically. If you want more heat, just turn the fan up, Lynch says. The best part is that with all of that oxygen, the fire burns more efficiently, which means you basically get no smoke.

Hear us out: The Apple Watch Series 5 may feel like just another iteration of a nonessential piece of tech an overpriced device to sit on your wrist and annoy you with constant notifications. But the updates that come with the Series 5 have finally turned the Apple Watch into a legitimate health-monitoring device. It can track your heart rate and warn you if you have irregular heart rhythms, or tell you when youre in an environment thats loud enough to damage your hearing. It can even notice that youve fallen and alert an emergency contact. Plus, the new iOS being launched this fallwill have automatic handwashing detection, helping you know youve actually scrubbing your hands for the recommended 20 seconds.

Code Jumper helps students who are blind or visually impaired gain an understanding of computer coding. Students can learn basic sequences and computational problem solving skills by physically maneuvering the blocks known as pods and plugs to create computer code. There are 19 lessons and 25 hours of instruction, which include tutorial videos about the basics of computer science.

This is a complete reinvention of the flashlight, says Strategist contributor Dan Dubno. The Nitecore is tiny less than three inches long but despite the size it gives off a brilliant, powerful beam up to 1,000 lumens in brightness, Dubno says. My favorite feature is the LED display, which lets you know exactly how much battery you have remaining at any of the five brightness settings youve selected. I can take a look at that display before [my dog] Charlie and I leave the house and know theres no chance of running out of juice in the middle of our walk.

Actually good deals, smart shopping advice, and exclusive discounts.

The Strategist is designed to surface the most useful, expert recommendations for things to buy across the vast e-commerce landscape. Some of our latest conquests include the best acne treatments, rolling luggage, pillows for side sleepers, natural anxiety remedies, and bath towels. We update links when possible, but note that deals can expire and all prices are subject to change.

Read this article:

14 Ingenious Gadgets That Will Improve Your Life 2020 | The Strategist - New York Magazine

Eye Health Supplements Market will Increase at High CAGR By 2027 | Global Industry Size, Share, Business Opportunities, Technology Advancement,…

Posted on July 21, 2020 by Danzig

CMI announced that its published an exclusive report namely Global Eye Health Supplements Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Eye Health Supplements Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.

The PDF Research only provides a Table of Contents (ToC), the scope of the report, and the research framework of the report.

Request PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/3791

The report presents an overview of Eye Health Supplements Market consist of objectives study and definition of Eye Health Supplements. The next section focuses on market size, region-wise Eye Health Supplements growth rate estimation from 2020-2027.

This research report categorizes the global market by players/brands, regions, types, and applications. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, and Porters Five Forces Analysis.

Key Manufacturers Analysis:Bausch + Lomb, Vitabiotics Ltd., Valeant Pharmaceuticals International Inc., Life Extension, Pfizer Inc., OmniActive Health Technologies, Algatechnologies, Alliance Pharma, The Natures Bounty Co., Novartis AG, and Amway Corp.

The top manufacturers, exporters, and retailers (if applicable) around the world are analyzed for this research report with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Eye Health Supplements Market 2020 Forecast to 2027 Market Segment by Regions, regional analysis covers

North America (the USA, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Columbia, etc.)The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Following market aspects are enfolded in Global Eye Health Supplements Market Report:

A wide summarization of the Global Eye Health Supplements Market. The present and forecasted regional market size data based on applications, types, and regions. Market trends, drivers, and challenges for the Global Eye Health Supplements Market. Analysis of company profiles of Top major players functioning in the market.

Eye Health Supplements Market report passes on a fundamental overview of the Market including its definition, applications, and advancement. Furthermore, the Industry report investigates the ecumenical Major Eye Health Supplements Market players in detail. Eye Health Supplements Market report gives key bits of the Cautiousness and subsisting status of the Players and is a basic Source obviously and heading for Companies and people energized by the Industry.

The Request Discount option enables you to get discounts on the actual price of the report. Kindly fill the form, and one of our consultants would get in touch with you to discuss your allocated budget and would provide discounts.

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/3791

Key questions answered in Report:-

Eye Health Supplements Business Analysis Including Size, Share, Key Drivers, Growth Opportunities and Trends 2020- 2027 Consumption Analysis of Eye Health Supplements, Guidelines Overview and Upcoming Trends Forecast till 2027 Eye Health Supplements Market Top Companies Sales, Price, Revenue and Market Share Outlook Eye Health Supplements Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027 Analytical Overview, Growth Factors, Demand and Trends Eye Health Supplements by Technology, Opportunity Analysis and Industry Forecasts, 2020- 2027 Analysis Covering Market Size, Growth Factors, Demand, Trends and Forecast Eye Health Supplements Overview, Raw Materials Analysis, Market Drivers and Opportunities In-depth Research on Market Size, Trends, Emerging Growth Factors and Forecasts.

Conclusively, this report will provide you a clear view of each fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Stay Home. Stay Safe. Save Lives.

New Government Bill will see automatic extension to planning permission due to expire since lockdown – On The Wight

Posted on July 21, 2020 by Danzig

Developers look set to be given more time to get their schemes started during the coronavirus crisis with the people behind the controversial 900-home Pennyfeathers development in Ryde looking likely to benefit.

Any planning permissions due to expire during the lockdown period have been extended.

Extension to three-year time limitA new Business and Planning Bill currently going through the Houses of Parliament will give new life to developments on the Isle of Wight and across the country.

One of the aspects of the bill includes extending the three-year time frameplanning permission is given for works to start.

Usually, if a development hasnt started within three years of approval then the permission expires but now housing secretary Robert Jenrick has proposed to extend it tohelp the construction industry get back on its feet after the first wave of the coronavirus.

This means if planning permission was due to expire anywhere from the start of lockdown in March until the end of 2020, it will automatically be extended to April 2021.

Extension for PennyfeathersOn the Isle of Wight, this will affect the controversial planning permission for Pennyfeathers the 900-house development near Westridge giving it more time to get started.

Before the new measures, the Ryde development had to be started before September and was under pressure to get conditions attached to the original permission changed so the project could run smoothly, according to its planning agents.

The government said the new measures will save more than 24,000 homes nationwide from not being built as planning expires.

Mr Jenrick said:

Building the homes the country needs is central to the mission of this government and is an important part of our plans to recover from the impact of the coronavirus.

Taken together, these measures will help to keep workers safe and our economy moving as we work together to bounce back from the pandemic.

IWC will comply with and implement legislation as required The Isle of Wight Council (IWC) said it will fully comply with the new measures, which will also help speed up planning appeals, when the legislation is passed.

A council spokesperson said:

As local planning authority (LPA), [the council] is aware of the Governments proposals as set out in the Business and Planning Bill and is tracking its progress through the legislative process with interest.

Once the Bill becomes law, the LPA will comply with and implement legislation as required.

Property specialists, BCM, who have a team and office on the Island, welcomed the new measures.

Howlett: A positive and proactive move to assist the industry Charlotte Howlett, planning consultant said:

The government has listened to the industry, something which will work to secure jobs and give the building supply chain certainty at this time.

After planning permissions are granted it takes an inordinate amount of time to resolve planning conditions, deal with statutory utilities, financing, building regulations, tender packages and contracts and so this extension provides essential time without the need to resubmit a new planning application, which would have otherwise submitted the same package as previously granted.

Covid-19 has had an effect on all businesses and so this allowance is a positive and proactive move to assist the industry.

This article is from the BBCs LDRS (Local Democracy Reporter Service) scheme, which OnTheWight is taking part in. Some alterations and additions may be been made by OnTheWight. Ed

Image: Google Maps/Streetview

Link:

New Government Bill will see automatic extension to planning permission due to expire since lockdown - On The Wight

Op-Ed: Addressing concerns about the future submarines from a generals perspective – Defence Connect

Posted on July 21, 2020 by Danzig

When the new submarine was being proposed, the media often asked if 12 was the right number of submarines to buy. The answer I always gave was trite but correct: It depends on what you want to do with them, explains NSW senator Jim Molan.

The single biggest issue for the submarine is how does it fit into a national defence strategy? At the time there was no real national defence strategy to assist the answer now there is.

The recently announced 2020 Strategic Update and Force Structure Plan assists in answering many of the questions about the Attack Class submarines: do we need them; why so big; how many; why conventional not nuclear; why not buy cheaper from overseas; are they vulnerable; when will we get them; what about the Collins; and why so expensive?

To summarise my position on the project as a whole, because of the war we may have to fight in the future and how we have decided to fight it, Australia needs submarines just as we need a range of surface ships and aircraft. We also need big submarines.

We need something in the order of 12; they are going to be conventional boats because nuclear is illegal in Australia and regardless, no one is going to lease or sell us nuclear boats. No one makes a conventional submarine big enough so we must build them as we built the Collins to meet our need, and there is a premium.

We are not taking the nuclear reactor out of a submarine and putting in a diesel engine we are designing these boats from a basic French design, as we did with the Collins.

They would probably have been built in South Australia regardless of the fact the Defence Minister came from there. Of course, I would rather they be available sooner than the mid-2030s to the mid-2050s, but we do have an effective submarine force in the Collins and we must keep it effective.

No one can criticise the Attack Class for not being effective submarines because at this stage they are still being designed and are likely to be a capable boat.

The French Submarine, as many of its detractors insist on calling it, has now become political, and some of the commentary is shrill. But we all have the right to a view, and to express that view, especially on the cost of the project if nothing else, and I respect others views.

This is the peoples money and the peoples future security. It is important for the project that we see frequent engagement by ministers, military chiefs and politicians.

We need to show that we believe in it, but also a more open explanation of what is behind and what is happening in the project in other words much more emphasis on informing the public rather than just rebuttal. In that spirit, I have stated where I stand.

The change in Australias defence strategy launched by the PM on 1 July was seismic and relevant to this issue. When considering any weapon system that has as much strategic, operational and tactical value as a submarine, and costs as much, it is wise to start with the overall strategy.

In essence, because of the change in our strategic environment, Australia now has a forward leaning defence strategy designed to shape the environment before conflict breaks out, to deter direct attacks on Australia, and if deterrence fails, to respond with force, another way of saying win.

The defence strategy says directly that Australia is able and willing to deploy military power to shape, deter and respond, which describes how we will fight the next war.

To implement what is essentially an operational concept, the government will allocate $270 billion over10 years for equipment, with manpower and operating costs additional.

To have the widest range of options for military commanders and governments in fighting future wars, we need submarines and big ones. The distances in our region are enormous, so they need endurance.

People forget how big the distances in our region are, or even just the length of our coast. We are not Sweden, Singapore, Germany or Norway. The distance from our east coast to our west coast is the same as that from London to Istanbul, regardless of whether we might want to deploy submarines to north Asia, the Indian Ocean or the South Pacific.

Big submarines are necessary for long deployments regardless of where the deployment goes, because one of the greatest assets of a submarine is to be on patrol for a long time and to hide.

In these days of wide area surveillance, submarines are vulnerable around their bases. As well, bigger boats can carry a range of weapons in addition to torpedoes, such as modern self-deploying sea mines, perhaps missiles or even special forces.

Bigger submarines then have options that do not involve returning to base to change loads.

Strategically, the role of submarines is to deter conflict by contributing to the operational and tactical defeat of an enemy force. Deterrence has the best chance of being achieved if a significant number of boats with a range of weapons can be deployed at any one time. A potential aggressor is never sure of their number or their location.

Nothing off-the-shelf can do this for Australia; the US are not going to lease nuclear boats to us. Apart from any considerations of national sovereignty and security, they also see the danger in our shared strategic environment. Starting this year, they are building three nuclear submarines each year, the most expensive US submarine building program since WW2.

This program, a combination of Columbia class ballistic missile boats and Virginia class attack submarines, is already stretching the USAs industrial capacity. We are on our own.

The number of boats needed by Australia is more difficult to quantify and twelve seemed arbitrary at the time, but not so much now within the current strategy.

The six Collins were intended to keep two operationally at sea most of the time which was world standard, and apparently now there are three Collins available for operational duties at any one time, another for training, one in light maintenance and one in deep maintenance, plus there is discussion of a life extension and upgrade.

Given the Attack Class submarines are unlikely to deliver operational capability until the mid- or late-2030s, the Collins will be around for a long time and then there will be a mix of Collins and Attacks.

The number of submarines needed to achieve deterrence for Australia in this new strategic environment will be well over six, probably at least nine, but 12 will be very good. Three to four submarines sustainably deployed is probably the strategic deterrent minimum and an operational one as well.

Some make the argument that the day of the submarine is over, that they can be found and destroyed now, and they are likely to be more vulnerable in the future.

Others of course make the point that nothing can survive in war on the surface of an ocean and so we should get rid of our surface ships. Everything in war is vulnerable to some extent, particularly mobile assets that operate in the atmosphere (aircraft and surface ships above the water) and fixed bases.

Advice is that research does not suggest to me that the relative difficulty of detecting submarines underwater by comparison with units which have to operate in the atmosphere is going to diminish. There is a big difference between getting an indication of a boat in an area and then localising it and a further difference between localising and achieving tracking quality sufficient to achieve a firing solution.

So you might know a submarine is around, but being able to destroy it is not as easy as some are saying. The updated strategy identifies the need for land-based anti-shipping missiles and I support this, while acknowledging that they are not a substitute for highly mobile submarines, surface combatants or aircraft, they are in addition.

For land-based missiles to survive in modern war, they need to be continually mobile, given the effectiveness of wide area surveillance.

Some related criticism of the Attack Class is that we are taking the nuclear reactor out of the French boat and replacing it with a diesel. That is unfairly simplistic and not the case. The Attack Class will be based on a French hull design but even that will be changed to suit our needs.

This boat is being designed now as a new vessel, and there are no grounds to say at this stage that it will not be an effective submarine.

I will not enter the argument of whether the costs have increased. Contracting and the costs have become a political issue and the ministers involved will handle that, but I acknowledge that everything in defence is expensive. We have tried fighting wars with the cheapest option and it does not go well.

Jim Molan is a senator for NSW. He retired as a major general from the Australian Army in 2008.

Op-Ed: Addressing concerns about the future submarines from a generals perspective

Original post:

Op-Ed: Addressing concerns about the future submarines from a generals perspective - Defence Connect

20 MLB bold predictions for 2020 season, including a big trade and the end of a World Series drought – CBS Sports

Posted on July 21, 2020 by Danzig

The 2020 Major League Baseball season is fast approaching. Summer camp is well underway and the mad dash 60-game season will soon begin. This season will be unlike any other season in MLB history -- it'll be the shortest season on record, there will be a universal DH, and there will be an extra-inning tiebreaker rule -- but it's baseball, and it'll be fun. It's OK to enjoy it.

To stick with the "20s" theme, here are 20 bold predictions for the 2020 baseball season. Come with me, won't you?

A record 6,776 home runs were hit in 2019, roughly 10 percent more than the previous record (6,105 in 2017). An independent committee attributed the homer spike to changes to the baseball itself, as well as hitters around the league buying into the launch angle craze. But mostly, it's the baseball. Pitchers complained it felt like a cue ball last season.

It seems crazy to suggest the baseball could be even more juiced next year, but a) these are bold predictions, and b) this has already happened once before. During that 2017 homer explosion, we all sat around and said, "wow, the ball can't possibly get more juiced than this," and then it was two years later. Baseball is a flat circle. Everythingthat's happened will happen again.

With an ultra-juiced baseball and MLB wanting to catch everyone's attention post-pandemic, we are boldly predicting 2,600 homers this season. That's a 7,000-homer pace in a full 162-game season. I feel good about this prediction because look at the ridiculous swing that led to Riley Greene's spectacular Endy Chavez style catch earlier in summer camp:

I know C.J. Cron has power, but good grief. That swing isn't supposed to produce a ball hit that far. The extra-juiced baseball will lead to several teams reaching the 120-homer plateau in 2020, or a record 324 home runs in a 162-game season. First bold prediction: dingers, and lots of 'em.

A late season groin injury sabotaged Ronald Acuna Jr.'s bid to become only the fifth 40/40 player in baseball history. The Braves wunderkind sat out the final four regular season games and finished with 41 home runs and 37 stolen bases. A National League leading 37 stolen bases, if you can believe it. It had been nearly 60 years since the NL leader stole that few bases.

For posterity's sake, here are the four 40/40 seasons in history:

Back in spring training Ozzie Albies toldFox Sports Souththat Acuna was "talking about 50/50" this season, though that won't happen in a 60-game season. Instead, our second bold prediction calls for Acuna to get to 20/20 in 2020. That's a 54/54 pace in a full 162-game season. It's doable. Likely? No, but doable, and I'm willing to bet on a player this talented.

If you give the Mets credit for the Johan Santana no-hitter, the Padres are the only MLB franchise without a no-hitter. The Marlins have been around roughly half as long as the Padres and they have six no-hitters. Six! Only five times in Padres history has the club completed eight no-hit innings in a game:

While there is something endearing about being the only MLB franchise not to do something cool like throw a no-hitter, our third bold prediction calls for the Padres to finally join the no-hit club this season. It's time. The San Diego franchise has played 8,136 regular season games and it's time to get through nine innings without allowing a base hit.

Specifically, I'll say slider specialist and personal fave Dinelson Lamet will start the historic game against the Mariners on Sept. 19 before giving way to relievers Drew Pomeranz and Kirby Yates. Lamet struck out 105 batters in 73 innings in his return from Tommy John surgery last season, you know. He's going to wake up one morning with no-hit stuff and, well, contribute to a no-hitter.

And order will be restored to the universe. Athletics slugger Khris Davis never seemed quite right last season -- he hurt his hip crashing into the wall in May and maybe that did it -- and he fought through a prolonged slump that saw him finish at .220/.293/.387. A's manager Bob Melvin even benched him at times. It was quite a fall for the 2018 American League home run leader.

The season-long slump put an end to one of the most fun streaks in recent baseball history. From 2015-18, Davis hit .247 in each season. Here are his batting averages carried out to an extra decimal place:

Davis hit .247 on the nose from 2015-18, because of course he did (OK fine, he really hit .2470081379). After a dreadful 2019, the bold prediction here is Davis will get back on the horse in 2020, and again hit a .247. (In case you're wondering, Khrush's batting average through 60 games last season was ... .241. So close!)

The five boroughs boast an impressive collection of power hitters. There's Aaron Judge and Giancarlo Stanton (and Gary Sanchez and Gleyber Torres) in the Bronx, and reigning NL Rookie of the Year and rookie home run record holder Pete Alonso in Queens. Those players I just mentioned have combined for three 50-homer seasons in the last three years.

And yet, it will not be one of those players who leads the two New York teams in home runs in 2020. It'll be Yoenis Cespedes, who has not played in roughly two years now because of heel surgeries and a boar-related ankle injury, but is healthy and has been crushing the ball in Summer Camp.

Cespedes is on track to the Mets everyday DH when the season opens. He won't have to worry about playing the outfield and that will reduce wear and tear, and improve his chances of staying healthy. Cespedes hit nine homers in 38 games prior to his injuries in 2018, a 38-homer pace, and he's playing for a contract. Few things in this sport are as fun as a locked in Cespedes and I am boldly predicting we will see that guy in 2020.

MLB teams have been signing their best young players to long-term contracts for more than two decades now. The craze started with the John Hart-era Cleveland teams in the 1990s. Teams are so extension happy nowadays that they've started signing players before they even make their MLB debuts. A complete list of pre-MLB debut extensions:

White spent the entire 2019 season in Double-A, yet the Mariners were still compelled to lock him up. They believe in him that much and there's so much upside. If he becomes the player they expect, Seattle will save tens of millions during the life of the contract. And, if White busts, the Mariners are out $4 million a year for six years. Middle reliever money. No big deal.

The next player to sign a long-term extension before making his MLB debut will be Orioles catcher Adley Rutschman, the No. 1 pick in the 2019 draft. He is an elite prospect -- Rutschman was arguably the best draft prospect since Bryce Harper in 2010 and he was quite clearly the best catching prospect since Buster Posey in 2008 -- and Baltimore will lock him up and soon.

My boldly predicted contract terms: 7 years and $60 million (covering 2021-27) with two club options that could bring the total value to $90 million. That would be the richest deal for a player yet to make his MLB debut and allow the Orioles to bring Rutschman to the big leagues at any point with no worry about service time. He's a special player and he'll get a special contract.

Which Mariner? Either Jarred Kelenic or Julio Rodriguez. I'd bet on it being Kelenic because I like his chances of playing in the big leagues this season, and with no proper minor-league season, it'll hard for players to improve their prospect stock at the alternate training site. Kelenic will see game action and have a chance to wow.

For what it's worth, our R.J. Anderson ranked Kelenic the No. 8 prospect in baseball over the winter(and Rodriguez the No. 41 prospect). Here's what R.J. had to say about Kelenic:

The gem of the Robinson Cano trade, Jarred Kelenic asserted himself as the top prospect in Seattle's system with an impressive age-19 season that saw him hit .291/.364/.540 with 23 homers and 20 steals across three levels -- including 21 Double-A contests. Perhaps unsurprisingly, Kelenic is expected to be an above-average hitter at the big-league level. Kelenic is more than just a stick though. He can run, and for the time being he's likely to remain in center thanks to his footspeed and his big-time arm. There's a chance he has to move to a corner (likely right) down the road, but there's star potential if he can stick up the middle. Kelenic won't be able to legally drink until July. By then, he could be knocking on the big-league door. Whether Seattle chooses to answer it before the 2021 season rolls around is to be seen.

Kelenic is on the short list of the game's top prospects and I boldly predict he will get enough MLB playing time this year to impress onlookers and improve his stock, but not enough to exceed the 130 at-bat rookie limit. He'll remain prospect eligible in 2021 and we'll see him atop top 100 prospect lists.

Blasphemous, I know. Mike Trout is well on his way to the inner circle of the inner circle of the Hall of Fame, plus we can't forget about new free agent pickup Anthony Rendon either. He's quite good. The thing is, Ohtani might be the most talented baseball player on the planet. It's not just me saying that either. At least one former opponent believes it:

"I keep saying this, and people always laugh at me when I say this, but he's the best baseball player I've ever seen in my life," CC Sabathia said on his podcast a few months ago. "Are you kidding me? He can hit the ball 900 feet and throw 99 off the mound. Who else can do that? Who else is doing that, bro? There's nobody else is doing that at the big-league level."

Ohtani is wrapping up his Tommy John surgery rehab and is expected to be in the Opening Day rotation. He turned only 26 earlier this month and, before his elbow gave out in 2018, he threw 51 2/3 innings with a 3.31 ERA and 63 strikeouts. He's also a career .286/.351/.532 hitter with 40 homers in 792 MLB plate appearance. All-Star production on both sides.

The total package, pitching plus hitting, will make Ohtani the most valuable player on his team this season. Trout is expected to step away at some point to be with his wife when she gives birth to their first child, which will cut into his production, but mostly, I just think Ohtani is that damn good. I can see him being a 4 WAR player in 60 games. It'll happen. It has been foretold.

But it won't be Luis Robert. Instead, it'll be fellow White Sox prospect Nick Madrigal. The 5-foot-7 second baseman slashed .311/.377/.414 with only 16 strikeouts in 120 minor-league games at three levels last season, including Triple-A. His 3.0 percent strikeout rate and 2.2 percent swing-and-miss rate were, by far, the lowest in the minors.

Here's what our R.J. Anderson wrote about Mr. Madrigal over the winter:

The No. 4 pick in the 2018 draft, Nick Madrigal is unlike most any other player in baseball. He's small and unlikely to offer much power, yet he's a good defensive second baseman with absurd bat-to-ball skills who "runs like a [mother's intimate friend]," in the words of one source.

Madrigal could arrive at any point during the shortened season -- he'll need to spend only seven days at the alternate site to push back his free agency -- and he has the skill set to grab the attention of Rookie of the Year voters. He's a flashy defender, he steals bases, and he makes so much contact that there is a chance he dinks and dunks his way to a .350 batting average. That'll play.

Robert is awesome, don't get me wrong, and his new extension ensures he will be on the Opening Day roster. The extra playing time could factor into the Rookie of the Year race. I think Robert could be in for an adjustment period though -- his swing-and-miss rate jumped to 21.1 percent in Triple-A last year -- allowing Madrigal to sneak in and steal the award, boldly.

Game 3 of the 2019 ALDS was Minnesota's 16th consecutive postseason loss, tying the 1975-79 Chicago Blackhawks for the longest postseason losing streak in the history of the four major North American pro sports. The Twins have not won a postseason game since Game 1 of the 2004 ALDS against the Yankees. Johan Santana started the game. Minnesota's starting lineup:

Not a single active major leaguer has played in a Twins postseason win. The last active player to appear in a Twins postseason win was Red Sox legend David Ortiz. He started his career in Minnesota and played his final big-league game on Oct. 10, 2016 (Game 3 of the 2016 ALDS against Cleveland). Yeah, it's been a long time since the Twins won a postseason game.

Fortunately for you, Twins fans, we are boldly predicting your team ends the postseason losing streak this year and gets back in the win column. Will they win a postseason series? Let's not get greedy. Win one game first. The Twins are a solid bet to return to the playoffs this year, likely as the AL Central champs, and they'll win a game in the ALDS (assuming they don't play the Yankees).

... again. One team won 96 games last season and is viewed as an up-and-coming powerhouse. The other won 93 games last year and is generally considered to be trending down. Pull the curtain back a little bit, and you can see the Rays and Cleveland were near carbon copies in 2019:

Runs scored

769

Runs allowed

657

656

Defensive efficiency

.709

.710

Team OPS

.756

.757

Team ERA

3.76

3.65

Freaky! Neither team got dramatically better over the winter either. Cleveland traded Corey Kluber, who was mostly a non-factor last year because of injuries. The Rays traded Tommy Pham and Emilio Pagan, arguably their best hitter and reliever, but have the depth to replace them. Point is, these two teams were extremely similar last season.

And I expect them to be extremely similar again this season. They're both deep in pitching with a few questions on the offensive side. For all the chatter that the Rays are built for a 60-game sprint, I feel like the same logic applies to Cleveland as well. They're a pitching factory with a manager who knows how to use it. Terry Francona's team is the sleeper your father thinks the Rays are.

... to the Phillies. Consider this is a three-pronged bold prediction. First, the Cubs are going to be bad (or simply mediocre) enough to actually sell at the Aug. 31 trade deadline. Second, Theo Epstein & Co. will actually go through with the whole selling thing. It's one thing to be in position to sell. It's another to actually act on it and trade away that big name player.

Here's what Epstein told the New York Post's Joel Sherman in March:

"It puts us in a position in which we have to be very objective about what we have," Epstein said. "In the middle of this season, if we have a legit World Series contender, that is really meaningful. But if we don't, you can't be blind to the realities of the following 18 months."

And third, the Phillies will be the team to bite and make the trade for Kris Bryant. Bryant was reportedly on the trade block all winter, and Philadelphia was said to be involved at various points, so connecting the dots again here hardly qualifies as bold. I guess the bold part of this prediction is the Cubs actually being out of it, and the Phillies offering enough to get a deal done.

What is enough to get a deal done? I'm going to say a multi-player package that is headlined by 2018 No. 3 pick Alec Bohm. A near MLB ready pitching prospect like Adonis Medina and JoJo Romerowill be the second piece. Sound good? The Phillies get a big third base bat while the Cubs get young talent and that all important financial flexibility.

The August 31 trade deadline will be weird. It's only a month into the season, so teams won't have much time to evaluate their roster and plot changes, and clubs will be wary of paying too much given the risk COVID-19 forces the season to be shut down at some point. Also, the shutdown is going to ruin payrolls for the foreseeable future. Money is tight.

That said, the Rockies and Tigers are in position to control the pitching market at the deadline because they're loaded with pitchers that are controllable beyond 2020. Consider: Jon Gray is under control through 2021, Matthew Boyd and Michael Fulmer are under control through 2022, Kyle Freeland is under control through 2023, and German Marquez is signed through 2023. Some of those guys are more available than others, but I can see a scenario in which all five are on the market.

Detroit has a plethora of young pitching coming (Matt Manning, Casey Mize, Tarik Skubal) and can afford to trade Boyd and/or Fulmer for multiple pieces to address other organizational needs. The Rockies need all sorts of help and those pitchers are their best way to get at this point. A Nolan Arenado trade probably isn't happening. Moving a starter is the next best thing.

Because this is a bold predictions piece, let's make some actual predictions. I'll say Boyd goes to the Astros for a package built around outfielder Kyle Tucker and pitching prospect Cristian Javier, and Gray goes to the Yankees for outfielder Estevan Florial and righty Albert Abreu. Sound good? Good.

The first impression of the new Globe Life Field in Texas is that it is "playing big as hell," according to slugger Joey Gallo. He has taken batting practice at the team's new digs in recent weeks and, for a guy with his power to say a ballpark is playing big, it must be playing really big.

"It's playing big as hell," Gallo told Jeff Wilson of the Fort Worth Star-Telegram in May. "It's definitely going to be a pitcher's park. We are trying to get those fences moved in a little bit. It's a little deep, I am not going to lie. It's a little deep out to center. Us hitters are getting a little nervous about that."

Globe Life Park, the team's old facility, was a notorious hitter's park, especially in the summer, when the ball flew in the Texas heat. The thing is, Globe Life Field's dimensions are generally cozier. Check it out:

Left field

332 feet

329 feet

Left-center

390 feet

372 feet

Center field

400 feet

407 feet

Right-center

377 feet

374 feet

Right field

325 feet

326 feet

The fence may be closer just about everywhere except dead center field, but there is more to how a ballpark plays than the outfield dimensions. The shape of the ballpark and how air moves through the structure matters, as does the retractable roof. It'll be nice and air conditioned now. Fans will love it. Alas, the cooler air means the ball will not travel quite as well.

Globe Life Park opened in 1994 and the park factors at FanGraphs say it inflated offense at least 3 percent every year of its existence, with most years in the 5-9 percent range. In Year 1 of Globe Life Field, I boldly predict the ballpark will suppress offense at least 3 percent below the league average. The Rangers will go from a bandbox to a cavern.

Toronto has been mired in fourth place since going to the ALCS in 2015 and 2016, so third place would represent their best finish in the standings in four years. The Blue Jays lost 95 games a year ago, but gosh, look at the young talent. Bo Bichette and Vladimir Guerrero Jr. are elite cornerstone types, and others like Cavan Biggio and Lourdes Gurriel Jr. are great complementary pieces.

Clubs with a great young talent base have a tendency to arrive ahead of schedule. The Twins did it just last year. The Rays in 2008, the Pirates in 2013, the Cubs in 2015 ... all those clubs were loaded with young talent and they all emerged sooner than expected. The Blue Jays spent some money on pitching this winter and those young bats make them a budding powerhouse.

Finishing in third place is unlikely to get the Blue Jays back to the postseason, but it does represent progress. I reckon Toronto will be a real headache to play in 2020. They won't be a pushover like many other non-contenders. And, of course, the Blue Jays finishing third means someone has to finish fourth, and I boldly predict it will be the Red Sox. A quick recap of their situation:

SportsLine has the Red Sox as an 33-win team at the moment. With the Blue Jays beginning their breakout and some things going wrong for the Red Sox, a fourth place finish is very possible. When the Red Sox are bad, they tend to be very bad (three last place finishes from 2012-15). Toronto breaks out, Boston breaks down, and the Blue Jays earn a third place finish in 2020.

A season ago Zac Gallen went from breakout prospect to hotshot rookie pitcher to traded at the deadline. He went from the Marlins to the Diamondbacks in July and pitched to a 2.89 ERA in eight starts in Arizona. Gallen's final MLB numbers: 2.81 ERA with 96 strikeouts and 2.7 WAR in 80 innings. Heck of a rookie year for the 24-year-old.

It's hard to call a guy who had a 2.81 ERA a year ago a breakout candidate, but Gallen is one, and I boldly predict he will place in the top three of the Cy Young voting in 2020. Ahead of wealthy new teammate Madison Bumgarner. Gallen is a five-pitch pitcher with command, and he misses bats with all five pitches. The numbers:

Four-seam fastball

23.7%

21.8%

Sinker

33.3%

15.5%

Cutter

27.4%

24.9%

Weakley Co. man sentenced to 23 years in federal prison for distributing meth – The Jackson Sun

Posted on July 21, 2020 by Danzig

Lasherica Thornton, Jackson Sun Published 6:55 a.m. CT July 17, 2020 | Updated 5:26 a.m. CT July 19, 2020

File photo.(Photo: Getty Images/iStockphoto)

A WeakleyCo. man was sentenced to more than 20 years for conspiracy to distribute methamphetamine following a 2018 investigation, according to a Thursday press release.

Keith Norris, 32 of Dresden, Tennessee, will spend 23 years in a federal prison for the charge, followed by five years of supervised release for the distribution of more than 296 oz. or 4.5 kilograms of meth.

Its the second sentencing in a case of conspiracy to distribute meth. The defendants Norris, Robert Thomas, Charles Settles, Justin Tyler Bynum and Solomon Clay face charges; Thomas was sentenced to nine years in federal prison, followed by five years supervised release for his role in the conspiracy.

"Drug distribution conspiracies are not victimless crimes, U.S. Attorney Michael Dunavant said. Methamphetamine causes significant human pain, loss, and destruction in countless ways, including addiction, injuries, and deaths.

Individuals who distribute harmful drugs into our rural communities can no longer hide, and those who choose to engage in such lawlessness will pay the price with a long prison sentence.

The Weakley County Sheriffs Department started an investigation into Norris for allegedly leading a drug trafficking organization. The investigation included search warrants, traffic stops, phone records and statements from people cooperating.

Norris was allegedly distributing meth to the five co-defendants. Investigators executed two searches at Norris house.

An April 2018 search recovered meth and more than $1,300. At a June 2018 search, investigators found Norris trying to destroy drug evidence. Police still recovered 4.5 ounces of meth, the release said.

When arrested, Norris claimed ownership of the drugs and let agents search his cell phone.

Based on his statement, Norris was held accountable for distributing 296 ounces of actual methamphetamine, which equates to over 4.5 kilograms of actual methamphetamine, the release said.

Lasherica Thornton is The Jackson Sun's education reporter. Reach her at 731-343-9133or by email at lthornton@jacksonsun.com. Follow her on Twitter: @LashericaT

Read or Share this story: https://www.jacksonsun.com/story/news/local/2020/07/17/weakly-co-man-gets-23-years-federal-prison-distributing-meth/5457058002/

Weakley Co. man sentenced to 23 years in federal prison for distributing meth - The Jackson Sun

Ex-pharmacist who admitted to diluting cancer drugs will not get out of prison early – KMBC Kansas City

Posted on July 21, 2020 by Danzig

A former pharmacist who diluted drugs for thousands of cancer patients will not be released from prison early, pending a review from the U.S. Department of Justice.Robert Courtney, 67, was scheduled to be transferred to a halfway house Thursday and then serve his remaining sentence under house arrest, but Sen. Josh Hawley and Rep. Emanuel Cleaver II said those plans have changed.The Department of Justice informed me this morning that they will not release Courtney from imprisonment, Hawley said. Cleaver said the Justice Department told him the release is still under review.Robert Courtney is a man who took advantage of public trust to commit abhorrent crimes that led to pain and suffering of hundreds, if not thousands, of Kansas Citians," Cleaver said. There are those in prison who have committed victimless crimes and are at high-risk of COVID-19 complications that, understandably, should be released for home confinement. However, Mr. Courtney is not one of these individuals. His crimes should disqualify him from early release, and Im hopeful as the Justice Department undergoes further review of this case they will come to the same conclusion.Hawley, Cleaver and other politicians called for Courtney to remain in prison when the news of his potential release from prison broke earlier this week.Thats the right call, Hawley said. COVID-19 should not be an opportunity at jailbreak for violent offenders.The original decision to release Courtney sparked outrage from the families that were impacted by his crimes."We lost a lot. He was a really great person," said Kathleen Duncan, daughter of Harry Duncan.Doctors told Harry Duncan that he had great odds of surviving his cancer. One year after he died, his family learned his pharmacist was Courtney."This man is a monster. I'm sorry. He's a murderer, and I don't know why he wasn't given longer than 30 years," Kathleen Duncan said.In 2002, Courtney was sentenced to 30 years in prison after pleading guilty. He admitted to diluting the prescription medications of 4,200 patients from 400 doctors. Some people received 1% of the dose they were prescribed."I'll never understand why they're letting him out 10 years early to be with his family," Duncan said."His ripple effect, I mean, just his victim pace is thousands of people," said Debra Allen.Allen's mother, Joyce Provance, died of ovarian cancer."He made all of his money. He cheated people based on health care and now, here we are in the biggest health care crisis of my lifetime, and it's getting him out of jail," Allen said.Attorney General William Barr originally directed the order for Courtney to be released because of the pandemic, but the Justice Department reversed course on Thursday.Missouri Gov. Mike Parson wrote Barr a letter on Wednesday requesting that he put a stop to Courtneys scheduled release.It is impossible to express the heartache and devastation brought about by his intentional criminal acts, and he should remain in prison until his sentence is complete, Parson said. I know these are troubling times and you are attempting to balance various needs. But this is a unique case and I urge your office to take a serious look at the release of Mr. Courtney.Elected officials Sen. Roy Blunt, Rep. Sam Graves, Hawley and Cleaver also sent letters to ask Barr to block the release.Courtneys crimes are heinous, the letter said. He inflicted a steep physical and emotional toll upon his victims for personal financial gain. He acted without consideration for the theft of his victims health and quality of life, and his actions can be described as no less than purposefully evil. Courtney should serve the entirety of his sentence as penance for his crimes both against his victims and against the public trust in medical care.The decision to release this individual fails to fully consider the public safety ramifications of his release and the impact that the release will have on his victims.After leaving the halfway house, Courtney had plans to live with family in Trimble, Missouri, which is north of Kansas City. Courtney had applied for compassionate release, which means his sentence could end early.

A former pharmacist who diluted drugs for thousands of cancer patients will not be released from prison early, pending a review from the U.S. Department of Justice.

Robert Courtney, 67, was scheduled to be transferred to a halfway house Thursday and then serve his remaining sentence under house arrest, but Sen. Josh Hawley and Rep. Emanuel Cleaver II said those plans have changed.

The Department of Justice informed me this morning that they will not release Courtney from imprisonment, Hawley said.

Cleaver said the Justice Department told him the release is still under review.

Robert Courtney is a man who took advantage of public trust to commit abhorrent crimes that led to pain and suffering of hundreds, if not thousands, of Kansas Citians," Cleaver said.

There are those in prison who have committed victimless crimes and are at high-risk of COVID-19 complications that, understandably, should be released for home confinement. However, Mr. Courtney is not one of these individuals. His crimes should disqualify him from early release, and Im hopeful as the Justice Department undergoes further review of this case they will come to the same conclusion.

Hawley, Cleaver and other politicians called for Courtney to remain in prison when the news of his potential release from prison broke earlier this week.

Thats the right call, Hawley said. COVID-19 should not be an opportunity at jailbreak for violent offenders.

The original decision to release Courtney sparked outrage from the families that were impacted by his crimes.

"We lost a lot. He was a really great person," said Kathleen Duncan, daughter of Harry Duncan.

Doctors told Harry Duncan that he had great odds of surviving his cancer. One year after he died, his family learned his pharmacist was Courtney.

"This man is a monster. I'm sorry. He's a murderer, and I don't know why he wasn't given longer than 30 years," Kathleen Duncan said.

In 2002, Courtney was sentenced to 30 years in prison after pleading guilty. He admitted to diluting the prescription medications of 4,200 patients from 400 doctors. Some people received 1% of the dose they were prescribed.

"I'll never understand why they're letting him out 10 years early to be with his family," Duncan said.

"His ripple effect, I mean, just his victim pace is thousands of people," said Debra Allen.

Allen's mother, Joyce Provance, died of ovarian cancer.

"He made all of his money. He cheated people based on health care and now, here we are in the biggest health care crisis of my lifetime, and it's getting him out of jail," Allen said.

Attorney General William Barr originally directed the order for Courtney to be released because of the pandemic, but the Justice Department reversed course on Thursday.

Missouri Gov. Mike Parson wrote Barr a letter on Wednesday requesting that he put a stop to Courtneys scheduled release.

It is impossible to express the heartache and devastation brought about by his intentional criminal acts, and he should remain in prison until his sentence is complete, Parson said. I know these are troubling times and you are attempting to balance various needs. But this is a unique case and I urge your office to take a serious look at the release of Mr. Courtney.

Elected officials Sen. Roy Blunt, Rep. Sam Graves, Hawley and Cleaver also sent letters to ask Barr to block the release.

Courtneys crimes are heinous, the letter said. He inflicted a steep physical and emotional toll upon his victims for personal financial gain. He acted without consideration for the theft of his victims health and quality of life, and his actions can be described as no less than purposefully evil. Courtney should serve the entirety of his sentence as penance for his crimes both against his victims and against the public trust in medical care.

The decision to release this individual fails to fully consider the public safety ramifications of his release and the impact that the release will have on his victims.

After leaving the halfway house, Courtney had plans to live with family in Trimble, Missouri, which is north of Kansas City. Courtney had applied for compassionate release, which means his sentence could end early.

Continue reading here:

Ex-pharmacist who admitted to diluting cancer drugs will not get out of prison early - KMBC Kansas City

Blackpool paedophile had collection of teething rings, clothes and baby magazines as well as vile indecent images of children being abused – Blackpool…

Posted on July 21, 2020 by Danzig

Matthew Matthiason, 34, who was staying at a property on Gorton Street, had a collection of indecent images, baby magazines, clothing, teething rings, anime books, a Japanese baby clothing catalogue and drawings depicting the sexual abuse of children.

Matthiason, who has a string of previous similar offences, admitted three counts of possessing indecent images, possessing prohibited images and breaching his order and has been jailed for 28 months.

He was handed an indefinite order and placed on the Sex Offender's Register for life in 2014 after repeatedly flouting court orders intended to prevent him from viewing indecent images of children.

Judge Simon Newell said: "The materials don't in themselves constitute an offence but are indicative of what has been admitted - a substantial, long standing, deeply embedded sexual interest in children

"It does appear you are not deterred by what may be seen as deterrent sentences.

"What that shows is that first of all this is long standing. It also indicates attempts by the courts whether by community sentences or suspended sentences or hospital treatment hasn't resolved the inclination you have, and the criminality that results in."

"These are not victimless crimes.

"Somewhere in the world possibly 2,000 children have been abused here so that those images can be put on the internet and so somebody has been sexually abusing those children - some babies and infants.

"That's an appalling thing to happen to any child and if it wasn't for the fact people like you were watching it, the bulk of this wouldn't happen."

Prosecuting, Kimberley Obrusik said officers carried out an unannounced visit at the hostel on April 18 but found no devices except a Playstation and phone on display.

Four days later they received intelligence he had downloaded indecent images and returned to arrest him, finding the books, clothes, drawings and material in his room, along with a black USB stick in his clothing.

Preston Crown Court was told his devices contained 434 category A images - 54 of them moving videos, 146 category B images including 19 videos, 1,454 category C images, including seven videos, and 345 prohibited images involving the drawings and other material.

Defending, Julie Taylor said he was "realistic" and knew it must be a custodial sentence.

She said: "He realised at 14 that he was attracted to children. He's refreshingly honest.

"He accepts he has a problem, he accepts he's a paedophile.

"He knows it's wrong and makes a valid point that while he understands image cases mean a child somewhere in the world has been abused to make that image, he himself has never tried to touch or harm a child himself."

She added he had lived in nine different hostels and had suffered constant threats to his life.

Read the original:

Blackpool paedophile had collection of teething rings, clothes and baby magazines as well as vile indecent images of children being abused - Blackpool...

Column: The real issues of the 2020 election | Opinions and Editorials | aikenstandard.com – Aiken Standard

Posted on July 21, 2020 by Danzig

After the 2020 campaign is finished, the next president will have to face huge, real problems in order to get the American ship of state back on course. It won't be easy. Hopefully, the winning candidate will have the wisdom, skill, ideas and advisers to do what needs to be done.

Honest people have to admit that our country is in a mess. Usually, the first year of a new administration is crucial; this time, it probably will take the first two years to get the most important things done. If we are going to get America moving again, these in my view are some of the real issues the next president and Congress must resolve.

First and foremost we have to get rid of the coronavirus which is plaguing our country and the world. America needs more testing and individuals need to take proper precautions to help prevent the spread of the disease. Next, we need a vaccine that is safe, effective and taken by everyone. Then, we need leaders who tell us the truth based on science and the facts. After that, we need affordable, comprehensive health insurance for all people, which is what every other developed nation has.

Second, we have to get our nation's children back to school. Returning kids to their schools requires a lot of new safety measures which cost money. We won't have the funds to do that if we keep cutting taxes on the rich and big corporations. We won't have the money for schools if we spend more on the military. President Trump pressured the European nations into spending more on their defense; but, Trump's budgets still increases U.S. military spending. Public education is one of the keys to our nation's strength. Every child in America, no matter their race, ethnicity, religion or where they live, deserves a quality education. A college education should also be available and affordable to all who want it. If we believe in equality of opportunity, education is the most important factor.

Third, we need to deal with economic and social inequality. America is becoming a have and have-not nation, with incomes and wealth moving upward to the top 10% of our population. If most of the economic power is concentrated in the hands of a few wealthy families and big corporations they will also have most of the political power. America is becoming an oligarchy or a plutocracy a government of, by and for the wealthy few not a democracy. Economic inequality can be alleviated by government action on taxes, the minimum wage and benefits, Social Security, etc., and also action on tax and antitrust laws to control the giant corporations. This is necessary to promote competition and prevent monopoly power.

Fourth, we need a better criminal justice system, one that works for everybody and enables the police to truly protect and serve. We can't have one system of justice for the rich and powerful and another system of justice for everybody else. Today, America has about 2.3 million people in jails and prisons; we have 5% of the world's population and 20% of the world's prisoners. How many of these people are in jail for victimless crimes? We should create alternatives to prison for nonviolent offenders. Since most people who are sent to prison eventually are released, how many of them are being rehabilitated and able to find useful work? Private, for-profit prisons are not the answer. The more people sent to prison, the more money these companies make.

Fifth, we need to rebuild our nation's crumbling infrastructure our roads, bridges, dams, tunnels, reservoirs, sewer and waste treatment facilities, public transportation and so forth. President Trump promised to do it, but he failed to deliver on his promise. Rebuilding our infrastructure will provide thousands of new, good-paying jobs for American workers.

Sixth, Congress must enact political reforms to get unlimited, secret, special-interest money out of politics. Two terrible Supreme Court decisions holding that money is speech and a corporation is a person must be overturned. These reforms are necessary to keep America democratic and free.

Other important things need to be done to restore America as that shining city on a hill for other countries to emulate. We need to cooperate with other nations in combating global warming/climate change, which is having disastrous effects worldwide: droughts, flooding in coastal areas and on islands, as well as the rapid melting of the polar ice caps.

Last, but not least, we need to keep our country out of unnecessary foreign wars. President Obama did and, so far, President Trump has, too. Will the next president be the leader we need? Will we insist on action to deal with these problems?

See original here:

Column: The real issues of the 2020 election | Opinions and Editorials | aikenstandard.com - Aiken Standard

Crackdown on Shoplifting in Normanton and Featherstone – West Yorkshire Police

Posted on July 21, 2020 by Danzig

Thursday 16 July 2020

Wakefield North East and Rural Neighbourhood Policing Team have targeted offenders shoplifting in Normanton and Featherstone.

In the last two months, 14 people have been arrested for shoplifting, they include:

Inspector Sohail Mohammed of Wakefield North East and Rural NPT said:

Shoplifting is a blight on retailers and we have been keen to assist them by reducing offences and taking action against thieves.

Shoplifting is not a victimless crime, it is a crime that affects retailer and the general public. Shoplifting represents a huge cost to retailers, and inevitably, to society as a whole.

We will continue to tackle these types of crime, and work effectively with businesses and partners to combat them. That includes dealing robustly with any abuse or violence offered to employees. Retailers have kept the country going and provided a valuable service to us all during unprecedented times

Im glad to see that the hard work of the neighbourhood policing team has paid off, and we have caught and prosecuted these offenders for these crimes.

Suspects for shoplifting are regularly uploaded to our Caught on Camera website and I would encourage anyone who recognises persons on there to contact the force on the contact details provided.

Read the original here:

Crackdown on Shoplifting in Normanton and Featherstone - West Yorkshire Police

Dean Blandino interview: What its really like to be an NFL official – prideofdetroit.com

Posted on July 21, 2020 by Danzig

When you think of the NFL and football, what do you think about? You probably think about a highly-intense, hard-hitting and overall fun game. Maybe you also think about giant contracts, endorsements, and all the flashy things. Thats what I do, too. Generally, our thoughts are positive, right? Besides the heartache you might feel when your team loses on Sunday or a player you like gets hurt, youre having a good time during the season.

Now think about what you know about NFL officials. Its probably all negative, right? These are the guys that wont just let the players play. These are guys that make the NFL the No Fun League. These are the guys that cost your team a regular season game or, even worse, a playoff loss. How much of the game do you spend yelling at the official on your TV? I would imagine its a lot.

But what do we really know about these guys? For most, its next to nothing. I get it. Its not the flashiest job in the world. We never seem to even talk about these guys unless were analyzing a really bad call or using them as the scapegoat after our teams loss.

This just wasnt good enough for me. I set out a few years ago to tell the human stories about the NFL. Ive spent all this time talking to players and completely ignoring everyone else whos on the field. Today we stop looking at the players, and we take a deep look into what its like to be an NFL official.

To get answers, we enlisted former NFL VP of Officiating and current Fox Sports analyst Dean Blandino. Detroit Lions fans might remember Blandino from their nightmares and possibly the worst moment of their fandom. Oh, you dont remember? Let me refresh your memories.

No, Blandino wasnt responsible for that call, but at the time, he was overseeing all NFL officials. He would later apologize to Detroit, and in recent years hes become something of a friend to Lions fans. Always willing to go on a podcast or even do an interview with Pride Of Detroit.

What Dean told us about the job was not at all what I was expecting. Heres a real look at what its like to be an NFL official.

Right off the bat it has to be known that you cant just submit your resume via Monster.com or something and become an NFL official. According to Blandino, its a very long vetting system that includes much more than just your performance on the field.

I dont know if many people really understand what goes into it when the NFL, when theyre considering hiring officials, Blandino said. This official has been scouted for years throughout their college career there. Theres Regional Scouts that are around the country that go and watch officials work games, and they create reports, and then you kind of monitor those officials and their progress.

Once an official gets to the highest level, theyll become a part of the officiating development program. And so thats a program that maybe 25-30 officials are there. They come to the NFL officiating Clinic they might work a preseason game and theyll get to spend time with NFL officiating crews, go to mini camps, OTAs and training camps to get kind of that feel for the NFL.

Thats just part of vetting process. At this point, prospective officials only have half their foot in the door. Once theyve completed and been approved from the development program, they have to go through a full background check that not only includes a criminal history check, but a look into their financial background, too. Theres also a full psychological exam and and a medical exam.

Pass all of that, and you have a chance to make it in the NFL. According to Blandino, even after you do all this and everything checks out fine, youre still not actually hired yet. All told, the process takes a few months.

Needless to say, the NFL is hiring who they deem to be the best of the best. While NFL fans may think the officials are incompetent at times, these guys were the guys that made it through a very difficult system.

After youve been hired, youre added to a team of officials. Each team has nine officials: Seven on the field and two in replay. The NFL does not just throw you on any team that needs a guy, though. Theres more to it than that.

That relationship when youre putting a crew together, youre not just looking at how they perform on the field, Blandino said. Youre thinking about personalities, how they interact with each other and communicate, because youre [together] for four preseason weeks and then 17 regular season weeks, then potentially postseason. Youre together a lot of times Friday, Saturday, Sunday and could be a Thursday night game. Youre together during the week, communicating during the week. And so those relationships, the more positive it is, the better your performance will be on the field. You deal with people you know in all of our professions. If we dont have positive relationships that can impact our performance.

Officials are given their assignments four weeks out. The officials are then in charge of setting up their travel arrangements. The league is partnered with American Express and they help the officials work out those plans. This includes hotels as well. The NFL has contracts with hotels in every NFL city.

The NFL also provides a per diem to officials for food, car rental, parking at the airport and parking at stadiums or city streets. All of this is set up in the leagues collective bargaining agreement. So in terms of finances and arrangements, NFL officials are set up pretty well.

But while the officials are not full time, they might as well be. A typical week for an official is a seven-day-a-week thing. Officials will usually arrive in their games city on Friday and wont leave till Sunday night or Monday morning depending on what time the game is at. Then they spend the rest of the week on conference calls, going through their video of the previous game, and then studying up on their next game. Its a very involved job. According to Blandino, some officials have other jobs, but spend way more time doing this than that.

With all the hard work and the constant traveling, it can be hard on an officials home life.

Its really hard, Blandino said. You talk to a lot of officials on the things that they miss out on. So many family events, whether its [the] biggest things, like birth of a child potentially to little league and graduations. All of these things that people in other professions may get to experience, officials sometimes lose out on because football season youre dealing withyou dont get to a lot of times celebrate Thanksgiving because you might be working or Christmas. Those fall and winter holidays are different than somebody else in another profession. So it is a major challenge to create that balance.

Weve all yelled at officialswhether it be from your couch or at the stadium. Covering high school and college sports I can tell you its definitely happening there too. Being the enemy is not fun and it can take a toll on you. With no satisfaction of victory, like the players, officials are just there to do a thankless job.

In officiating, you dont have those wins and losses, Blandino said. Youre more just trying to avoid mistakes, and its not an environment where youre getting a lot of positive reinforcement. And, for the most part, everything you do is critiqued and scrutinize to such a degree, and theres always going to be some group of people regardless of what the call is. And the call could be absolutely correct, and some people arent going to like it and theyre going to think its wrong.

These mistakes arent victimless crimes. Its not always about a win or loss. Sometimes an official making a mistake can cost someone else, whether it be a player or a coach, their job.

I know one official that was involved in a controversial call going back and missed the call, and it cost the team of game, Blandino said. Ultimately, the coaching staff got fired and and [the official] went into a depression and put it on himself, started drinking, just not taking care of himself.

Its hard to completely blame the officials. The system the crews use sometimes sets them up to fail. Its important to remember that these guys dont see what we see on TV.

The reality is that they get one look at it on the field in real time, Blandino said. Then we get the benefit of all these replays, and we get to scrutinize them based on information that they dont really even have. Thats the hard part. But its thats the nature of the business and everybody that goes into officiating understands that they dont go in thinking that theyre going to get a lot of pats on the back.

From a fan standpoint, the truth is that a lot of calls lead to anger. American sports fans are an incredibly passionate bunch of people. That passion has sadly led to some hideous things when it comes to officials. Whether it be cyber bullying, death threats or much worsefans finding out where officials live and throwing bricks through their windows or having their cars vandalized, two things Blandino said has happened to NFL officials.

Thankfully, the NFL has some protections in place. No official will ever work a game in the city they live in, protecting them from potentially livid fans in their own backyard. The league also has security set up for the officials to report things like death threats and fans throwing bricks through their windows. But all the security in the world doesnt protect you from being a human being with feelings.

Luckily for officials, Blandino says its tight knit group of people that look out for each other and help each other get through these types of situations. If youve long believed that these guys dont care, those beliefs are wrong. Nobody likes to make mistakes, especially mistakes that can hurt the job security of someone else or even make fans feel unhappy. This is a very stressful job.

The mistakes will likely never stop. According to Blandino, the game is too fast. The officials simply dont have the same view of the game that fans at home or the stadium do. They simply only have whats in their line of sight. Sure, they will go to the video on big things or refer to the New York office for even bigger things, but on simple calls like holding or hands to the face, there are always going to be missed calls or bad calls. You just cant see everything down there.

Dean says there are always things in the works to alleviate the bad or missed calls as well as the stress on officials. One thing thats being discussed is the addition of a sky judge. This would be an extra official in the box who has a full field view, as well as access to video replay. They can communicate with the officials on the field with what they saw and potentially change poor calls.

The NFL is also not just allowing officials who make plenty of mistakes to keep making those mistakes without being held accountable. Like any job, officials are being graded for their performance every week. As a matter of fact, theyre being graded on every single play. The performance is then evaluated by the NFL, and if the score is poor enough, officials could face what's called a downgrade.

The NFL places officials into three different tiers. That top tier means that you get to work the playoffs. Working the playoffs obviously means more money. If the review board believes youve made a bad call, you can be downgraded to the next tier. You can also be upgraded if you make a really tough, but correct call too. If you make enough bad calls youll be downgraded out of your job.

I hope that after you read this you come away with a different point of view on NFL officials or officials in general. This is not an easy job. Theres a lot of negativity there. Im not saying you shouldnt be emotional about the sport and your team. Im also not saying you shouldnt be emotional about the calls on the field. But maybe keep in mind that these are human beings that feel all the same ways you do but have way more eyes and a lot of pressure on them at all times. Maybe its time we all understand that this is not an easy job.

Dean Blandino interview: What its really like to be an NFL official - prideofdetroit.com

Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry – PharmiWeb.com

Posted on July 21, 2020 by Danzig

The 2020 annual report released today presents Cell and Gene Therapy Catapults achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.

London UK, 20 July 2020 The Cell and Gene Therapy Catapult (CGT Catapult) has today published its Annual Review 2020, highlighting achievements and initiatives from the past year which are enhancing growth and productivity in the UK cell and gene therapy industry.

It has been another year of progress for the UK cell and gene therapy industry, with 12% of global advanced therapy medicinal product (ATMP) clinical trials taking place in the UK, with over 3,000 jobs created in the sector, and over 90 advanced therapy developers currently based in the UK.

Among many milestones achieved over the year is the construction of new modules at the CGT Catapult manufacturing centre in Stevenage which are now fully operational, doubling capacity for collaboration at the facility. This expansion, which was funded by 3.36m from the European Regional Development Fund (ERDF) and 12m from the Industrial Strategy Challenge Fund (ISCF), provides additional infrastructure and expertise to anchor global cell and gene therapy manufacturing in the UK.

CGT Catapult initiatives have also made a significant impact in the industry over the past twelve months:

10 spin-out companies and small and medium enterprises (SMEs) have been provided with tailored support through commercial readiness advice clinics, a programme launched in November 2019 and part funded by 3.5m from the ERDF

The Advanced Therapy Treatment Centre (ATTC) network, funded by the ISCF and coordinated by CGT Catapult, now has 6% of global ATMP clinical trials run through its centres, and the network works with 64 partners in industry, academia and healthcare providers

The number of Advanced Therapies Apprenticeship Community (ATAC) apprentices, an initiative funded by the ISCF, has more than doubled compared with 2019, helping to tackle the demand for skills in the industry

Matthew Durdy, CEO, Cell and Gene Therapy Catapult said:

Strong Government support through Innovate UK has enabled CGT Catapult to innovate and collaborate to further advance the UK cell and gene therapy ecosystem over the past year, making it globally attractive for the commercialisation of cell and gene therapies. Moving forward, we strive to continue our mission to create more high value employment and make more life-changing therapies a therapeutic reality for patients around the world.

During these times of uncertainty amidst the COVID-19 pandemic, we are also helping to supporting companies to continue innovating, and in doing so enable further economic growth in this pioneering industry.

Ian Muir, Director Healthcare & Lifesciences, Innovate UK commented:

The Cell and Gene Therapy Catapult goes from strength to strength. It is playing a vital role in growing the UK cell and gene therapy industry, placing the UK in a world leading position, helping companies to grow.

These therapies are now getting to patients and Innovate UK is looking forward to continue to support the Cell and Gene Therapy Catapult and its initiatives such as its skills programme and Advanced Therapy Treatment Centres.

You can access the Cell and Gene Therapy Catapult 2019-20 Annual review at: ct.catapult.org.uk/annualreviews

About the Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 230 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.

About the European Regional Development Fund

The CGT Catapult manufacturing centre expansion phase and the commercial readiness advice clinics programme received funding from the England European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020. The Ministry of Housing, Communities and Local Government (and in London the intermediate body Greater London Authority) is the Managing Authority for the European Regional Development Fund. Established by the European Union, the European Regional Development Fund helps local areas stimulate their economic development by investing in projects which will support innovation, businesses, create jobs and local community regenerations. For more information visit https://www.gov.uk/european-growth-funding.

About the Industrial Strategy Challenged Fund

This CGT Catapult manufacturing centre expansion phase, Advanced Therapy Treatment Centre (ATTC) network and Advanced Therapy Apprenticeship Community (ATAC) have been funded by the Industrial Strategy Challenge Fund, part of the governments modern Industrial Strategy. The fund is delivered by UK Research and Innovation. The Industrial Strategy Challenge Fund is a four-year, 1 billion investment in cutting-edge technology designed to create jobs and improve living standards, built on guidance from business and the academic community. Healthcare and Medicine is one of three core areas for investment under the programme.

Read the original post:

Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry - PharmiWeb.com

Gene Therapies for Cancer Treatment to Witness Growth Acceleration During 2019-2025 – Jewish Life News

Posted on July 21, 2020 by Danzig

Global Gene Therapies for Cancer Treatment Market Growth Projection

The new report on the global Gene Therapies for Cancer Treatment market is an extensive study on the overall prospects of the Gene Therapies for Cancer Treatment market over the assessment period. Further, the report provides a thorough understanding of the key dynamics of the Gene Therapies for Cancer Treatment market including the current trends, opportunities, drivers, and restraints. The report introspects the micro and macro-economic factors that are expected to nurture the growth of the Gene Therapies for Cancer Treatment market in the upcoming years.

The report suggests that the global Gene Therapies for Cancer Treatment market is projected to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key indicators such as the year-on-year (Y-o-Y) growth and CAGR growth of the Gene Therapies for Cancer Treatment market are discussed in detail in the presented report. This data is likely to provide readers an understanding of qualitative and quantitative growth prospects of the Gene Therapies for Cancer Treatment market over the considered assessment period.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2692433&source=atm

The report clarifies the following doubts related to the Gene Therapies for Cancer Treatment market:

Segmentation of the Gene Therapies for Cancer Treatment Market

The adoption pattern of each product is analyzed in the presented study with relevant graphs, tables, and figures.

The scenario of the Gene Therapies for Cancer Treatment market in each regional market is discussed in the report.

The following players are covered in this report:Takara BioTocagenVBL TherapeuticsCold GenesysGenprexMomotaro-GeneMultiVirSynerGene TherapeuticsZiopharm OncologyAnchiano TherapeuticsCelgeneCelsionBluebird BioGene Therapies for Cancer Treatment Breakdown Data by TypeSomatic Cell Gene Therapy (SCGT)Germline Gene Therapy (GGT)Gene Therapies for Cancer Treatment Breakdown Data by ApplicationCancer Research CentersDiagnostic LaboratoriesCancer HospitalsOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2692433&source=atm

Vital Information Enclosed in the Report

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2692433&licType=S&source=atm

See original here:

Gene Therapies for Cancer Treatment to Witness Growth Acceleration During 2019-2025 - Jewish Life News

Cancer Gene Therapy – Market Share Analysis and Research Report by 2025 – CueReport

Posted on July 21, 2020 by Danzig

New research report on Cancer Gene Therapy market, which is a detailed analysis of this business space inclusive of the trends, competitive landscape, and the market size. Encompassing one or more parameters among product analysis, application potential, and the regional growth landscape, Cancer Gene Therapy market also includes an in-depth study of the industry's competitive scenario.

Some major findings of the cancer gene therapy market report include:

- Increasing mortality rates due to cancer has created a huge demand for cancer gene therapies

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/23090

Cancer Gene Therapy Market size is expected to exceed USD 2.5 billion by 2025. Rising cancer prevalence across the globe will positively impact the cancer gene therapy market growth.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/23090

- Regulations for cancer gene therapy are quite structured and stringent in developed economies such as the U.S. and Germany while the regulatory scenario is still ambiguous in emerging economies

- Cancer gene therapy industry is still in developing phase and yet to witness numerous growth opportunities in the coming years

- Technological advancements in the biotechnology sectors has led to developments in the cancer gene therapy that are being now preferred by healthcare professionals

- Some of the major industry players include Sirion Biotech, Vigene Biosciences, bluebird bio, Ziopharm, Cellectis, Cobra, Finvector, Uniqure, Sarepta Therapeutics, Caribou among others. These industry players adopt several strategic initiatives to maintain their market position.

Technological advancements in the biotechnology sector have led to developments and innovations in cancer gene therapy. Recently developed cancer therapies have been incorporated with genetically modified genes that blocks the growth of tumor. Moreover, efficient PCR technology and isothermal amplification technologies have been introduced that transformed the way of detecting mutations in the genes. Moreover, introduction of CRISPR gene editing tools have modified the process of developing gene therapy. Hence, advancements in technology has ensured availability of advanced cancer gene therapy that will boost the industry growth. However, high cost of cancer gene therapy may impede its demand, thereby restraining the industry growth to certain extent.

Type segment of cancer gene therapy market includes ex-vivo and in-vivo. In-vivo segment is projected to experience around 22% growth throughout the analysis timeframe owing to various advantages associated with it. In-vivo gene therapy involves direct delivery of therapeutic gene into the target cell and has shown effective results in treatment of cancer. The viral vectors that are delivered utilizing in-vivo gene therapy help in inhibiting the activity of tumor inducing genes and has also shown positive results during clinical trials. Aforementioned factors will elevate the segmental growth.

Products of cancer gene therapy include viral vectors and non-viral vectors. Viral vectors segment was valued over USD 310 million in 2018. Viral vectors are highly preferred during gene transfer process as they have showcased high transfection efficiency. Viral vectors possess safety profile as compared to other vectors. Moreover, viral vectors expresses the desired antigen in accurate conformation enhancing the immune system.

End-users of cancer gene therapy are biopharmaceutical companies, research institutes and others. Biopharmaceutical companies segment accounted for around 48% revenue share in 2018 and is expected to experience exceptional growth in the forthcoming years. Companies such as Novartis and Roche are developing cancer gene therapies that have high adoption of viral as well as non-viral vectors, thereby proving beneficial for the segmental growth. These companies also conduct clinical trials that raises the demand for vectors, hence fostering the segmental growth.

China cancer gene therapy market will experience over 26% CAGR throughout the forecast years. Significant country growth can be attributed to the rising awareness regarding the availability of advanced therapies for treating cancer. Furthermore, increasing government initiatives and funds motivate the researchers and scientists for carrying out extensive research activities associated with cancer gene therapy that will positively influence the country growth. Above mentioned factors coupled with increasing prevalence of cancer will further stimulate the industry growth.

Cancer gene therapy industry is dominated by few major players. Cancer gene therapy industry is still in the developing phase, therefore, players involved in thie market focus on integrating advanced technology to promote developments in the therapies. The players also implement certain strategic initiatives such as merger, acquisitions and product launches for acquiring competitive advantage. For instance, in 2013, Celgene and bluebird bio collaborated to introduce innovations in gene therapies. Such collaborations will provide both the companies to gain competitive advantage over others.

Major Highlights from Table of contents are listed below for quick lookup into Cancer Gene Therapy Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Cancer Gene Therapy industryInsights

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/23090

Excerpt from:

Cancer Gene Therapy - Market Share Analysis and Research Report by 2025 - CueReport

Homology Medicines Appoints Jeff Poulton to the Board of Directors – GlobeNewswire

Posted on July 21, 2020 by Danzig

- Executive with Extensive Rare Disease Expertise in Global Finance andCommercial Operations -

BEDFORD, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Jeff Poulton has been appointed to the Board of Directors. Mr. Poulton is the Chief Financial Officer at Alnylam. Mr. Poulton brings 25 years of experience to Homologys Board of Directors, including leading finance, business development and commercial operations at companies using differentiated technologies to develop treatments for patients with rare diseases.

I had the pleasure of working with Jeff before, and I know first-hand how his strategic financial and operational leadership contributed to the success of a global rare disease commercial business, said Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. Jeff has also displayed a long-term commitment to help patients and their families, which aligns with Homologys mission to develop our gene therapy and nuclease-free gene editing platform into new treatments and potential cures. He joins at an important time in the development of our pipeline, and we look forward to his guidance as we progress our Phase 1/2 pheNIX gene therapy clinical trial for adults with PKU and work toward bringing our other development candidates to the clinic.

Prior to his role at Alnylam, Mr. Poulton served as CFO at Indigo Agriculture where he supported the initial commercial scale-up of the business, including expansion outside the US. Mr. Poulton previously held various roles of increasing responsibility at Shire Plc, concluding his service as CFO and a member of its Executive Committee and Board of Directors. During his tenure at Shire, Mr. Poulton led the rare disease commercial operations in the US, Latin America, and Asia Pacific, as well as its global rare disease business unit. Prior to Shire, he led corporate finance and business development initiatives in both the energy and materials manufacturing sectors in financial leadership positions at Cinergy Corp and PPG industries. He also served in the US Navy as a Commissioned Officer. Mr. Poulton has an MBA in Finance from the Kelley School of Business at Indiana University and a bachelors degree in Economics from Duke University. He also serves as a member of the Board of Directors at EIP Pharmaceuticals.

I am drawn to companies with transformative technologies, and I believe Homologys genetic medicines platform has the potential to change the lives of patients with rare diseases, said Mr. Poulton. I look forward to working with the team at Homology, many of whom have successful careers in developing and commercializing drugs at prior companies that are continuing to make a positive impact in the lives of patients and families living with rare diseases.

About Homology Medicines, Inc. Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homologys proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicinesin vivoeither through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visitwww.homologymedicines.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our genetic medicines platform; the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; and our position as a leader in the development of genetic medicines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the capabilities and potential expansion of our manufacturing facility; risks relating to the regulatory approval process; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 and our other filings with theSECcould cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

See the rest here:

Homology Medicines Appoints Jeff Poulton to the Board of Directors - GlobeNewswire

Global Gene Therapy in Oncology Market Analysis, Research, Share, Growth, Sales, Trends, Supply, Forecast by 2026 – 3rd Watch News

Posted on July 21, 2020 by Danzig

Aimed at offering report readers with updated information as well as market relevant cues to leverage uninhibited growth in the Gene Therapy in Oncology market, this intricately researched, designed, and articulated real-time reference of the Gene Therapy in Oncology market is a culmination of in-depth research mettle and best in class primary and secondary research initiatives that collectively influence a favorable growth trajectory in the Gene Therapy in Oncology market. The report is a ready-to-refer market specific representation that is designed to equip report readers with market specific information attributed to multi-dimensional facets and features that tend to have tangible effect on the growth prospects in the Gene Therapy in Oncology market.

Get a Sample Copy of Report: https://www.orbispharmareports.com/sample-request/24437?utm_source=Nilam

The report highlights massively the core growth propellants such as market driving factors, prevailing challenges and the like that tend to have a negative growth impact on the global Gene Therapy in Oncology market. Further, to encourage readers in a decisive, transparent and meticulous declassification of the growth factors, this section of the report also sheds substantial light upon potential opportunity profile as well as a highly effective barrier analysis that together encourage sturdy growth in the global Gene Therapy in Oncology market.

Major companies of this report:

Bristol-Myers SquibbCold GenesysAdvantageneAmgenAstraZenecaBio-Path HoldingsCRISPR TherapeuticsEditas MedicineGeron CorpIdera PharmaceuticalsIntellia TherapeuticsJohnson & JohnsonMarsala BiotechMerckMologen AGOncolytics BiotechOncosecOncotelicShenzhen SiBiono GeneTechSillajen BiotherapeuticsTocagenUniQureZiopharm OncologyGene Therapy in Oncology

Browse Full Report at: https://www.orbispharmareports.com/global-gene-therapy-in-oncology-market-2020-2026-report-by-type-applications-manufacturers-and-regional-overview/?utm_source=Nilam

Other relevant facets of the Gene Therapy in Oncology market has also been elaborated in the subsequent sections of the report, thus allowing market players, established participants and stakeholders, besides upcoming market aspirants to selectively decode vital details in the ambit of product portfolio, technological sophistication, application matrix, end-use populace that collectively direct the growth potential in global Gene Therapy in Oncology market. In continuation with all the above market specific information furnished above, the report further in its subsequent sections also throws light upon other additional yet pertinent details that further channelize revenue generation in the Gene Therapy in Oncology market. In this context, this section of the report highlights vital understanding on the basis of revenue generation nuances, as well as numerous other high-end information and data synthesis with respect to the aforementioned Gene Therapy in Oncology market that execute profit maximization.

Market Segment by Type, covers:

Ex VivoIn VivoGene Therapy in Oncology

Market Segment by Applications, covers:

HospitalsDiagnostics CentersResearch Institutes

In tandem with all the aforementioned market specific information, this report in its subsequent sections also illustrates definitive information about segment analysis that identifies type, application, technological advances as well as competition landscape as major segments. All the above furnished information about the Gene Therapy in Oncology market has been meticulously drawn from dedicated primary and secondary research initiatives and verified by internationally acclaimed analytical practices comprising PESTEL and SWOT analysis to derive logical conclusions. Further, a dedicated section on competition spectrum comprising the top tier players in the Gene Therapy in Oncology market has also been tagged in the concluding sections of this report to encourage logical business discretion.

Make an enquiry of this report @ https://www.orbispharmareports.com/enquiry-before-buying/24437?utm_source=Nilam

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Original post:

Global Gene Therapy in Oncology Market Analysis, Research, Share, Growth, Sales, Trends, Supply, Forecast by 2026 - 3rd Watch News

Zolmitriptan Market Size, Growth Trends, Top Players, Application Potential and Forecast to 2026 – Cole of Duty

Posted on July 21, 2020 by Danzig

Market Study Report, LLC, has added a research study on Zolmitriptan market which offers a concise summary regarding market valuation, market share, regional spectrum, revenue estimation and SWOT analysis of this business vertical. The report further brings up key insights pertaining to growth opportunities and challenges to be experienced by key industry players, while emphasizing on their present competitive setting and growth plans for the Zolmitriptan Market.

The Zolmitriptan market report assess this business space in terms of revenue estimations as well as consumption patterns over the estimated timespan. The report comprises of granular evaluation of the manufacturing behemoths and the gross remuneration amassed by them. The unit cost implemented by these industry players across regional fragments is also cited in the study.

Request a sample Report of Zolmitriptan Market at:https://www.marketstudyreport.com/request-a-sample/2633629?utm_source=coleofduty.com&utm_medium=Ram

Vital data regarding the product consumption value alongside volume is stated in the document. The report also offers information related to the respective sale prices, consumption rates, and import & export conditions.

The COVID-19 pandemic has compelled governments across the globe to impose lockdown in order to reduce the spread of the disease, which has halted the operations of various manufacturing and industrial facilities. Moreover, the lack of labor workforce and limited availability of raw material is predicted to cause modifications in the Zolmitriptan market during the forecast period.

An overview of the geographical terrain:

A summary of the product landscape:

An outlook of the application spectrum:

Ask for Discount on Zolmitriptan Market Report at:https://www.marketstudyreport.com/check-for-discount/2633629?utm_source=coleofduty.com&utm_medium=Ram

A gist of the competitive arena:

Briefly, the research report on Zolmitriptan market offers vital data such as upstream raw materials, equipment utilized, and downstream buyers. The report also evaluates the factors that are fueling the market size and the individual strategies adopted by the leading market contenders.

Major Highlights from Table of contents are listed below for quick look up into Zolmitriptan Market report

For More Details On this Report: https://www.marketstudyreport.com/reports/global-zolmitriptan-market-research-report-2020-segment-by-key-companies-countries-types-applications-and-forecast-2021-to-2026

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Zolmitriptan Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

1. Global Ferritin Market Research Report 2020, Segment by Key Companies, Countries, Types, Applications and Forecast 2021 to 2026Ferritin market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.Read More: https://www.marketstudyreport.com/reports/global-ferritin-market-research-report-2020-segment-by-key-companies-countries-types-applications-and-forecast-2021-to-2026

2. Global Nootropics Market Research Report 2020, Segment by Key Companies, Countries, Types, Applications and Forecast 2021 to 2026Nootropics Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on.Read More: https://www.marketstudyreport.com/reports/global-nootropics-market-research-report-2020-segment-by-key-companies-countries-types-applications-and-forecast-2021-to-2026

Zolmitriptan Market Size, Growth Trends, Top Players, Application Potential and Forecast to 2026 - Cole of Duty

Select Page ::